Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

First Posted Date
2024-02-16
Last Posted Date
2024-02-16
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
60
Registration Number
NCT06262438
Locations
🇳🇱

Princess Máxima Center for pediatric oncology, Utrecht, Netherlands

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

First Posted Date
2024-02-08
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
36
Registration Number
NCT06247787
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

C S Mott Children's Hospital, Ann Arbor, Michigan, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 10 locations

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

First Posted Date
2024-01-30
Last Posted Date
2024-12-10
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
216
Registration Number
NCT06230224
Locations
🇨🇳

Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan

🇹🇷

VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey

🇦🇺

Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

and more 54 locations

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

First Posted Date
2024-01-24
Last Posted Date
2024-08-22
Lead Sponsor
Children's Hospital of Soochow University
Target Recruit Count
500
Registration Number
NCT06221683
Locations
🇨🇳

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

🇨🇳

XiangYa Hospital Central South University, Changsha, Hunan, China

🇨🇳

Children's Hospital of Soochow University, Suzhou, Jiangsu, China

and more 10 locations

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

First Posted Date
2024-01-18
Last Posted Date
2024-05-17
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT06210750

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

First Posted Date
2023-12-20
Last Posted Date
2024-12-16
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
24
Registration Number
NCT06177067
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

First Posted Date
2023-12-19
Last Posted Date
2023-12-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
150
Registration Number
NCT06175702

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date
2023-11-09
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
680
Registration Number
NCT06124157

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

First Posted Date
2023-09-22
Last Posted Date
2024-03-05
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
60
Registration Number
NCT06050941

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

First Posted Date
2023-09-13
Last Posted Date
2024-07-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
30
Registration Number
NCT06034470
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy